Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.45 |
| ▸ | RXRA | P19793 | 2/20 | 0.45 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.45 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.45 |
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | USP28 | Q96RU2 | 3/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3208881 | 0.93 | LMNA (0.50) | CAMKK2LMNAPTGS2MEN1ALDH1A1 | |
| SCHEMBL3211567 | 0.88 | LMNA (0.53) | LMNAPTGS2USP28 | |
| SCHEMBL3199738 | 0.86 | LMNA (0.54) | LMNAPTGS2USP28 | |
| SCHEMBL29374737 | 0.85 | CAMKK2 (0.59) | CAMKK2PTGS2RXRAPFKFB3CSNK2A2 | |
| SCHEMBL2342732 | 0.85 | CAMKK2 (0.59) | CAMKK2PTGS2RXRAPFKFB3CSNK2A2 | |
| SCHEMBL3205630 | 0.82 | TSHR (0.55) | MEN1ALDH1A1KMT2ARXRA | |
| SCHEMBL4252833 | 0.80 | KMO (0.59) | CAMKK2LMNAPTGS2ALDH1A1RXRA | |
| SCHEMBL3216304 | 0.80 | EGFR (0.51) | RXRA | |
| SCHEMBL3211804 | 0.79 | KMO (0.62) | LMNAMEN1KMT2ARXRA | |
| SCHEMBL16566150 | 0.79 | MAPT (0.56) | CAMKK2PTGS2MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | claimed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | CAMKK2 1334/4885LMNA 1934/4885PTGS2 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.